PMID- 23788757
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20200206
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 9
DP  - 2013 Sep
TI  - HER2 status in gastric cancers: a retrospective analysis from four Chinese 
      representative clinical centers and assessment of its prognostic significance.
PG  - 2360-4
LID - 10.1093/annonc/mdt232 [doi]
AB  - BACKGROUND: HER2 has a predictive value in gastric cancer. However, its 
      association with prognosis remains uncertain. The aim of our study was to 
      estimate the HER2-positive rate in Chinese gastric cancers, compare the classical 
      fluorescence in situ hybridization (FISH) method with the novel bright-field dual 
      color silver-enhanced in situ hybridization (DSISH) detection system, and 
      evaluate the relationship between the HER2 status and prognosis. PATIENTS AND 
      METHODS: Seven hundred and twenty-six resected gastric cancers separately from 
      four clinical centers in China were examined for HER2 by immunohistochemistry 
      (IHC), FISH, and DSISH. RESULTS: The HER2-positive rate was 13%. The consistency 
      between FISH and DSISH results was high (99%; kappa = 0.958; P < 0.001). Tumor 
      heterogeneity and polysomy were the main reasons for inconsistency. There was no 
      significant difference in the 3-year overall survival (OS) between HER2-positive 
      and -negative patients (P = 0.959). Multivariate analysis showed that HER2 was 
      not an independent prognostic factor. CONCLUSION(S): HER2 overexpression and 
      amplification occur in a significant number of Chinese gastric cancer patients. 
      Given the obvious advantages and high consistency with FISH, DSISH was superior 
      for evaluating HER2 amplification in gastric cancer. HER2 was not a prognostic 
      factor for gastric cancer in our study.
FAU - Sheng, W Q
AU  - Sheng WQ
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
FAU - Huang, D
AU  - Huang D
FAU - Ying, J M
AU  - Ying JM
FAU - Lu, N
AU  - Lu N
FAU - Wu, H M
AU  - Wu HM
FAU - Liu, Y H
AU  - Liu YH
FAU - Liu, J P
AU  - Liu JP
FAU - Bu, H
AU  - Bu H
FAU - Zhou, X Y
AU  - Zhou XY
FAU - Du, X
AU  - Du X
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130619
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - China
MH  - Gene Amplification
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*metabolism/*mortality/pathology
MH  - Survival
OTO - NOTNLM
OT  - FISH
OT  - HER2
OT  - dual SISH
OT  - gastric cancer
OT  - immunohistochemistry
OT  - prognosis
EDAT- 2013/06/22 06:00
MHDA- 2014/05/16 06:00
CRDT- 2013/06/22 06:00
PHST- 2013/06/22 06:00 [entrez]
PHST- 2013/06/22 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - S0923-7534(19)36956-X [pii]
AID - 10.1093/annonc/mdt232 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Sep;24(9):2360-4. doi: 10.1093/annonc/mdt232. Epub 2013 Jun 19.